Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revlimid plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (MM-010)
NCT00424047Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Jan 2003
- Primary completion
- Nov 2005
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in multiple myeloma (MM) comparing Revlimid + Dexamethasone with Placebo + Dexamethasone (2 arms). Primary endpoint: Time to Tumor Progression at 51 months. Started Jan 2003; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00424047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00424047.